期刊名称 anti-cancer drugs
期刊缩写 ANTI-CANCER DRUG
学科分类 医学、生命科学、化学
出版周期 月刊
审稿速度 1个月 （平均）
投稿命中率 不详
期刊主页 http://journals.lww.com/anti-cancerdrugs/pages/issuelist.aspx
ISSN 号 0959-4973
IF 趋势 2005 2006 2007 2008 2009 2010 2011 2012
1.907 2.245 2.357 2.358 2.23 2.376 2.407 2.232
被收录情况 1. Science Citation Index
2. Science Citation Index Expanded
3. Current Contents - Clinical Medicine
4. Current Contents - Life Sciences
5. BIOSIS Previews
PubSci评语 专注于抗癌药物及其相关的药物设计、药物输送及药理学等方面。审稿速度快，一审在一个月以内，审稿人的意见很中肯，对语言和图片要求高，需要按照美式英语修改。
期刊简介 Anti-Cancer Drugs主要发表于抗癌药物相关的基础和临床研究成果，并欢迎抗癌药物设计、药物输送、药理学、激素和生物方式及化疗评估方面的论文投稿。旨在通过快速出版抗癌方面的治疗药物，加速对有毒和无毒抗肿瘤药物的研究。
投稿注意事项 特别提醒：印刷形式发表的彩图需要作者额外支付费用。无版面费。
一般注意事项：
Note: These instructions comply with those formulated by the International Committee of Medical Journal Editors. For further details, authors should consult the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” at www.icmje.org.
The Journal is a member of the Committee on Publication Ethics (COPE) which aims to define best practice in the ethics of scientific publishing (www.publicationethics.org).
SCOPE
Anti-Cancer Drugs is devoted to the rapid publication of innovative investigations on therapeutic agents against cancer and methods to diminish adverse effects of drugs. The journal publishes peer reviewed articles on anti-cancer drug design, drug delivery, pharmacology and chemotherapy evaluation.
POINTS TO CONSIDER WHEN SUBMITTING YOUR PAPER TO ONE OF OUR JOURNALS
Please think carefully about the following points and make the appropriate declarations.
Redundant or duplicate publication
We ask you to confirm that your paper has not been published in its current form or a substantially similar form (in print or electronically, including on a web site, or in another language), that it has not been accepted for publication elsewhere, and that it is not under consideration by another publication. The International Committee of Medical Journal Editors has provided details of what is and what is not duplicate or redundant publication (www.icmje.org). If you are in doubt (particularly in the case of material that you have posted on a web site), we ask you to proceed with your submission but to include a copy of the relevant previously published work or work under consideration by other journals. In your covering letter to the editors, draw attention to any published work that concerns the same patients or subjects as the present paper.
Conflicts of interest
Authors must state all possible conflicts of interest in the manuscript, including financial, consultant, institutional and other relationships that might lead to bias or a conflict of interest. If there is no conflict of interest, this should also be explicitly stated as none declared. All sources of funding should be acknowledged in the manuscript. All relevant conflicts of interest and sources of funding should be included on the title page of the manuscript with the heading “Conflicts of Interest and Source of Funding:”. For example:
Conflicts of Interest and Source of Funding: A has received honoraria from Company Z. B is currently receiving a grant (#12345) from Organization Y, and is on the speaker’s bureau for Organization X – the CME organizers for Company A. For the remaining authors none were declared.
In addition, each author must complete and submit the journal’s copyright transfer agreement, which includes a section on the disclosure of potential conflicts of interest based on the recommendations of the International Committee of Medical Journal Editors, “Uniform Requirements for Manuscripts Submitted to Biomedical Journals“ (www.icmje.org/update.html). The form is readily available on the manuscript submission page www.editorialmanager.com/acd and can be completed and submitted electronically. Please note that authors may sign the copyright transfer agreement form electronically. For additional information about electronically signing this form, go to http://links.lww.com/ZUAT/A106.
Permissions to reproduce previously published material
We ask you to send us copies of permission to reproduce material (such as illustrations) from the copyright holder. We cannot send your paper to press without these permissions!
Patient consent forms
The protection of a patient's right to privacy is essential. We ask you to send copies of patient consent forms on which patients or other subjects of your experiments clearly grant permission for the publication of photographs or other material that might identify them. If the consent form for your research did not specifically include this, please obtain it or remove the identifying material. A sample patient consent form is available from the Journal’s website if required.
Ethics committee approval
You must state clearly in your submission in the Methods section that you conducted studies on human participants must with the approval of an appropriate named ethics committee. Please also look at the latest version of the Declaration of Helsinki. Similarly, you must confirm that experiments involving animals adhered to ethical standards and must state the care of animal and licensing guidelines under which the study was performed.
Authorship
We ask all authors to confirm that they have read and approved the paper. Second, we ask all authors to confirm that they have met the criteria for authorship as established by the International Committee of Medical Journal Editors, believe that the paper represents honest work, and are able to verify the validity of the results reported. In addition to those from the ICJME the International Society for Medical Publication Professionals, ISMPP (www.ismpp.org) have produced some useful guidelines on authorship of studies sponsored by companies: Good Publication Practice (GPP2) (www.ismpp.org).
Compliance with NIH and Other Research Funding Agency Accessibility Requirements
A number of research funding agencies now require or request authors to submit the post-print (the article after peer review and acceptance but not the final published article) to a repository that is accessible online by all without charge. As a service to our authors, LWW will identify to the National Library of Medicine (NLM) articles that require deposit and will transmit the post-print of an article based on research funded in whole or in part by the National Institutes of Health, Wellcome Trust, Howard Hughes Medical Institute, or other funding agencies to PubMed Central. The Copyright Transfer Agreement provides the mechanism.
Copyright assignment
Papers are accepted for publication on the understanding that exclusive copyright in the paper is assigned to the Publisher. Authors are asked to submit signed copyright assignment forms with their paper. They may use material from their paper in other words published by them after seeking formal permission.
Submissions
Authors are strongly encouraged to submit their manuscripts through the web-based tracking system at http://www.editorialmanager.com/acd. The site contains instructions and advice on how to use the system. Authors should NOT in addition then post a hard copy submission to the editorial office, unless you are supplying artwork, letters or files that cannot be submitted electronically, or have been instructed to do so by the editorial office. Should authors have difficulty in uploading files contact the Editor, Dr Mels Sluyser at e-mail: m.sluyser@planet.nl in the first instance, but do not send your files.
Double spacing should be used throughout the manuscript, which should include the following sections, each starting on a separate page: Title Page, abstract and keywords, text, acknowledgements, references, individual tables and captions. Margins should be not less than 3 cm. Pages should be numbered consecutively, beginning with the Title Page, and the page number should be placed in the top right hand corner of each page. Abbreviations should be defined on their first appearance in the text; those not accepted by international bodies should be avoided.
Authors are invited to list up to four potential reviewers, including their full addresses, telephone and fax numbers, and e-mail addresses.
PRESENTATION OF PAPERS
Title Page
The Title Page should carry the full title of the paper and a short title to be used as a ‘running head’ (and which should be so identified). The first name, middle initial and last name of each author should appear. If the work is to be attributed to a department or institution, its full name should be included. Any disclaimers should appear on the Title Page, as should the name and address of the author responsible for correspondence concerning the manuscript and the name and address of the author to whom requests for reprints should be made. Finally, the Title Page should state conflicts of interest and source of funding, and when none state “none declared”.
Abstracts
The second page should carry a structured abstract of no more than 250 words. The abstract should state the Objective(s) of the study or investigation, basic Methods (selection of study subjects or laboratory animals; observational and analytical methods), main Results (giving specific data and their statistical significance, if possible), and the principal Conclusions. It should emphasise new and important aspects of the study or observations.
Key Words
The abstract should be followed by a list of 3–10 keywords or short phrases which will assist the cross-indexing of the article and which may be published. When possible, the terms used should be from the Medical Subject Headings list of the National Library of Medicine (http://www.nlm.nih.gov/mesh/meshhome.html).
Text
Full papers of an experimental or observational nature may be divided into sections headed Introduction, Methods (including ethical and statistical information), Results and Discussion (including a conclusion), although reviews may require a different format.
Acknowledgements
Acknowledgements should be made only to those who have made a substantial contribution to the study. Authors are responsible for obtaining written permission from people acknowledged by name in case readers infer their endorsement of data and conclusions.
References
References should be numbered consecutively in the order in which they first appear in the text. They should be assigned Arabic numerals, which should be given in brackets, e.g. [17], [17, 19-23]. References should include the names of all authors when six or fewer; when seven or more, list only the first six names and add et al. References should also include full title and source information. Journal names should be abbreviated as in MEDLINE (NLM Catalog,http://www.ncbi.nlm.nih.gov/nlmcatalog).
Articles in journals
Standard journal article:
Ravaud A, Bello CL. Exposure–response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice. Anticancer Drugs 2011; 22:377–383.
More than six authors:
Umemura S, Yamane H,Yano T, Hoshika T, Shiote Y, Takigawa N, et al. Synchronous double primary lung cancers with different response to pemetrexed. Anticancer Drugs 2011; 22:473–476.
Supplements:
Gianni AM, Berinstein NL, Evans PAS, López-Guillermo A, Solano C. Stem-cell transplantation in non-Hodgkin’s lymphoma: improving outcome. Anticancer Drugs2002; 13 (suppl): S35–42.
Books
Book:
DeVita VT, Hellman S, Rosenberg SA. Cancer: principles & practice of oncology, 7th edn. Philadelphia: Lippincott Williams & Wilkins, 2005.
Chapter in a book:
Restifo NP, Wunderlich JR. Cancer Immunology. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of oncology, 7th edn. Philadelphia: Lippincott Williams & Wilkins, 2005: 139-161.
Personal communications and unpublished work should not feature in the reference list but should appear in parentheses in the text. Unpublished work accepted for publication but not yet released should be included in the reference list with the words ‘in press’ in parentheses beside the name of the journal concerned. References must be verified by the author(s) against the original documents.
Tables
Each table should be typed on a separate sheet in double spacing. Tables should not be submitted as photographs. Each table should be assigned an Arabic numeral, e.g. (Table 3) and a brief title. Vertical rules should not be used. Place explanatory matter in footnotes, not in the heading. Explain in footnotes all non-standard abbreviations that are used in each table. Identify statistical measures of variations, such as standard deviation and standard error of the mean.
Be sure that each table is cited in the text. If you use data from another published or unpublished source, obtain permission and acknowledge the source fully.
Illustrations
A) Creating Digital Artwork
Learn about the publication requirements for Digital Artwork: http://links.lww.com/ES/A42
Create, Scan and Save your artwork and compare your final figure to the Digital Artwork Guideline Checklist (below).
Upload each figure to Editorial Manager in conjunction with your manuscript text and tables.
B) Digital Artwork Guideline Checklist
Here are the basics to have in place before submitting your digital artwork:
Artwork should be saved as TIFF, EPS, or MS Office (DOC, PPT, XLS) files. High resolution PDF files are also acceptable.
Crop out any white or black space surrounding the image.
Diagrams, drawings, graphs, and other line art must be vector or saved at a resolution of at least 1200 dpi. If created in an MS Office program, send the native (DOC, PPT, XLS) file.
Photographs, radiographs and other halftone images must be saved at a resolution of at least 300 dpi.
Photographs and radiographs with text must be saved as postscript or at a resolution of at least 600 dpi.
Each figure must be saved and submitted as a separate file. Figures should not be embedded in the manuscript text file.
Remember:
Cite figures consecutively in your manuscript.
Number figures in the figure legend in the order in which they are discussed.
Upload figures consecutively to the Editorial Manager web site and enter figure numbers consecutively in the Description field when uploading the files.
References to figures and tables should be made in order of appearance in the text and should be in Arabic numerals in parentheses, e.g. (Fig. 2).
If hard copies are submitted they should have a label pasted to the back bearing the figure number, the title of the paper, the author’s name and a mark indicating the top of the figure. Illustrations should be presented to a width of 82 mm or, when the illustration demands it, to a width of 166 mm.
Photomicrographs must have internal scale markers.
If photographs of people are used, their identities must be obscured or the picture must be accompanied by written consent to use the photograph.
If a figure has been published before, the original source must be acknowledged and written permission from the copyright holder for both print and electronic formats should be submitted with the material. Permission is required regardless of authorship or publisher, except for documents in the public domain.
Figures may be reduced, cropped or deleted at the discretion of the editor.
Colour illustrations are acceptable but authors will be expected to cover the extra reproduction costs (for current charges, contact the publisher).
Legends for illustrations
Captions should be typed in double spacing, beginning on a separate sheet of paper. Each one should have an Arabic numeral corresponding to the illustration to which it refers. Internal scales should be explained and staining methods for photomicrographs should be identified.
Units of measurement
Measurements of length, height, weight, and volume should be reported in metric units (metre, kilogram, or litre) or their decimal multiples. Temperatures should be given in degrees Celsius. Blood pressures should be given in millimetres of mercury.
All haematologic and clinical chemistry measurements should be reported in the metric system in terms of the International System of Units (SI). Editors may request that alternative or non-SI units be added by the authors before publication.
Abbreviations and symbols
Use only standard abbreviations. Avoid abbreviations in the title and abstract. The full term for which an abbreviation stands should precede its first use in the text unless it is a standard unit of measurement.
Supplemental Digital Content
Supplemental Digital Content (SDC): Authors may submit SDC via Editorial Manager to LWW journals that enhance their article's text to be considered for online posting. SDC may include standard media such as text documents, graphs, audio, video, etc. On the Attach Files page of the submission process, please select Supplemental Audio, Video, or Data for your uploaded file as the Submission Item. If an article with SDC is accepted, our production staff will create a URL with the SDC file. The URL will be placed in the call-out within the article. SDC files are not copy-edited by LWW staff, they will be presented digitally as submitted. For a list of all available file types and detailed instructions, please visit http://links.lww.com/A142.
SDC Call-outs
Supplemental Digital Content must be cited consecutively in the text of the submitted manuscript. Citations should include the type of material submitted (Audio, Figure, Table, etc.), be clearly labeled as "Supplemental Digital Content," include the sequential list number, and provide a description of the supplemental content. All descriptive text should be included in the call-out as it will not appear elsewhere in the article.
Example:
We performed many tests on the degrees of flexibility in the elbow (see Video, Supplemental Digital Content 1, which demonstrates elbow flexibility) and found our results inconclusive.
List of Supplemental Digital Content
A listing of Supplemental Digital Content must be submitted at the end of the manuscript file. Include the SDC number and file type of the Supplemental Digital Content. This text will be removed by our production staff and not be published.
Example:
Supplemental Digital Content 1.wmv
SDC File Requirements
All acceptable file types are permissible up to 10 MBs. For audio or video files greater than 10 MBs, authors should first query the journal office for approval. For a list of all available file types and detailed instructions, please visit http://links.lww.com/A142.
Offprints
Offprints may be purchased using the appropriate form that will be made available with proofs. Orders should be sent when the proofs are returned; orders received after this time cannot be fulfilled.
编辑部信息 所在地： 阿姆斯特丹 国家 荷兰
Editor-in-Chief
Mels Sluyser, PhD
The Netherlands Cancer Institute-H4
Plesmanlaan 121
1066 CX Amsterdam
The Netherlands
Phone: +31 35 52 59 943
m.sluyser@planet.nl
网友投稿经验整理：
研究方向：肿瘤 审稿时间:约1个月 SCI(2012)：2.232
1. 审稿速度较快，3周修回。
2. 补实验1月后二审，直接接受。
3. 这个杂志效率挺高的，审稿人的意见挺中肯的，不会故意刁难，对文字的要求没有像之前说的这么严格。
贡献者： 183.157.160.14
杂志名称：Anti-cancer Drugs
专业领域：肿瘤、药物
杂志国家：美国
2007年影响因子：2.347
投稿日期：2008.11.5
投稿方式（投稿系统或者邮寄，如果有投稿系统请附上投稿链接）：http://www.editorialmanager.com/acd/
修回日期：2008.12.1
修改方式（大修，小修，拒稿）：拒稿
接受日期：否
是否收版面费：No
分享的经验或教训：
1、审稿速度很快，一般一个月就回来了；
2、审稿人美国本土人较多，所以对语言要求较高，要按照美式英语进行反复修改，我就是因为语言问题被两位审稿人拒了；
3、要按照稿约精心准备，尤其是结果的图片，因为该杂志属于Lippincott Williams & Wilkins数据库，所以对图片的格式要求较高；
4、最后也是最重要的就是文章一定要有新意，近年来该杂志IF上升较快，而且审稿人很挑剔，文章较偏药物抗肿瘤的基础研究。
贡献者：kaijiewu
对语言和图片要求高。要求本土语言。
一般3周会有回音。
贡献者：紫琳
投稿后一月修回，二审1个月后拒稿
分享的经验或教训：对语言和图片要求高。要求本土语言。
贡献者：wdcmm1975
SCI(2010)：2.376
3分边缘的杂志，影响因子变化不大，相对来说，适合咱们中国人投稿
贡献者：
